PEGS Boston 2026 Resources
Thank you for connecting with us a PEGS Boston 2026!
Presentations
- 1 in 3 MAbs Binds off-Target: How to Predict and Avoid Adverse Events Caused by Polyspecificity
- 100+ Undruggable Targets Unlocked through Parallel MAb Engineering
- Title: CDR-Scanning for Antibody Engineering and New IP: Deep mutagenesis enables parallel engineering for affinity, developability, and patentability
- Title: Antibody Reagents to Validate Impossible Protein Targets: High-quality mAbs for previously intractable GPCRs & ion channels
- Title: A New Approach Methodology (NAM) for Specificity Testing: ISTAND qualification of the Membrane Proteome Array to evaluate off-target binding of MAb-based therapies
Download our Posters
A New Approach Methodology (NAM) for Specificity Testing: ISTAND qualification of the Membrane Proteome Array to evaluate off-target binding of MAb-based therapies
CDR-Scanning for Antibody Engineering & New IP: Comprehensive mutagenesis enables parallel engineering of affinity, developability, and patentability
Antibodies against 100+ Impossible Protein Targets: High-quality mAbs for previously intractable GPRCs, ion channels, & transporters
Learn more about our products and services
Biotherapeutic specificity testing services featuring the Membrane Proteome Array™
- Membrane Proteome Array
- Specificity Insights Blog: Current Developments in Antibody Specificity Testing
Paratope-PLUS® CDR-scanning service: experimental data for antibody engineering and intellectual property
Cell Surface Bio: Extensively validated recombinant antibodies with unparalleled specificity against difficult targets
